Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.49 |
| ▸ | ATM | Q13315 | 1/20 | 0.49 |
| ▸ | ADRB2 | P07550 | 2/20 | 0.48 |
| ▸ | ADRB1 | P08588 | 2/20 | 0.48 |
| ▸ | ADRB3 | P13945 | 2/20 | 0.48 |
| ▸ | DNM1 | Q05193 | 2/20 | 0.48 |
| ▸ | BCHE | P06276 | 4/20 | 0.46 |
| ▸ | BACE1 | P56817 | 1/20 | 0.46 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.45 |
| ▸ | ANPEP | P15144 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.45 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11962073 | 0.83 | MEN1 (0.48) | MEN1KMT2AADRB2ADRB1ADRB3 | |
| SCHEMBL1327171 | 0.82 | MAPT (0.60) | MEN1KMT2AADRB2ADRB1ADRB3 | |
| SCHEMBL17005472 | 0.82 | MAPT (0.60) | MEN1KMT2AADRB2ADRB1ADRB3 | |
| SCHEMBL2306548 | 0.82 | MAPT (0.60) | MEN1KMT2AADRB2ADRB1ADRB3 | |
| SCHEMBL9170630 | 0.81 | ADRB2 (0.45) | MEN1KMT2AADRB2ADRB1ADRB3 | |
| SCHEMBL25868650 | 0.79 | HPGD (0.52) | MEN1KMT2AADRB2ADRB1ADRB3 | |
| SCHEMBL893963 | 0.79 | BCHE (0.63) | MEN1KMT2ADNM1BCHEBACE1 | |
| SCHEMBL23964580 | 0.78 | MAPT (0.50) | ADRB2ADRB1ADRB3DNM1BCHE | |
| SCHEMBL23386838 | 0.78 | KDM4E (0.50) | MEN1KMT2AADRB2ADRB1ADRB3 | |
| SCHEMBL24473808 | 0.78 | CA1 (0.60) | ADRB2ADRB1ADRB3DNM1BCHE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11767301-B2 | Bi-functional molecules to degrade circulating proteins | YALE UNIVERSITY (US) | 2023-09-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11767301-B2 | Bi-functional molecules to degrade circulating proteins | MIF, ASGR1, FCGR2A | MEN1 1417/4885KMT2A 4646/4885ATM 4373/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.